Tetraphase Pharmaceuticals Inc. (Nasdaq: TTPH) reported positive results from a Phase 3 clinical trial of eravacycline lifting the stock price 98 cents to close at $7.88.
Positive test results for Tetraphase Pharmaceuticals
July 26, 2017 at 17:11 PM EDT
